R
Roger Stupp
Researcher at Northwestern University
Publications - 463
Citations - 73077
Roger Stupp is an academic researcher from Northwestern University. The author has contributed to research in topics: Temozolomide & Glioma. The author has an hindex of 93, co-authored 430 publications receiving 63025 citations. Previous affiliations of Roger Stupp include Merck & Co. & University of St. Gallen.
Papers
More filters
Journal ArticleDOI
CAR T-Cell Therapies in Glioblastoma: A First Look
Denis Migliorini,Pierre-Yves Dietrich,Roger Stupp,Gerald P. Linette,Avery D. Posey,Carl H. June +5 more
TL;DR: Results from three first-in-man chimeric antigen receptor (CAR) T- cell trials targeting IL13Rα2, Her2/CMV, and EGFRvIII address important questions, such as T-cell trafficking to CNS, engraftment and persistence, tumor microenvironment remodeling, and monitoring of glioma response to CAR T cells.
Journal Article
Combined modality therapy of head and neck cancer.
TL;DR: The treatment of head and neck cancer has traditionally consisted of surgery with postoperative radiation therapy as mentioned in this paper, and chemotherapy has been reserved for palliation, which has been shown to be effective for head cancer patients.
Journal ArticleDOI
New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy
TL;DR: Temozolomide and Gliadel (carmustine wafers) are generally well tolerated due to their limited systemic toxicity and appear particularly well suited for incorporation into multimodal treatment strategies.
Journal ArticleDOI
Anaplastic astrocytoma in adults
TL;DR: Based on randomized data available, chemotherapy has consistently failed to improve the outcome of patients with anaplastic astrocytoma, while a meta-analysis showed a small, but significant improvement in survival favouring the use of chemotherapy.
Journal ArticleDOI
Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group
Roger Stupp,W. Mason,M. J. van den Bent,M. Weller,Barbara Fisher,M. J. B. Taphoorn,A. A. Brandes,Gregory Cairncross,Denis Lacombe,R.O. Mirimanoff +9 more
TL;DR: This randomized trial tested a novel regimen of TMZ concomitantly and adjuvant to RT against standard therapy of GBM after biopsy or resection for survival advantage in patients with histologically proven newly diagnosed GBM.